Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) EV-to-FCF: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$27.56
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hanx Biopharmaceuticals (Wuhan) Co's Enterprise Value is HK$3,727.27 Mil. Hanx Biopharmaceuticals (Wuhan) Co does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF at this moment.

The historical rank and industry rank for Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF or its related term are showing as below:

HKSE:03378' s EV-to-FCF Range Over the Past 10 Years
Min: -32.34   Med: 0   Max: 0
Current: -32.34
HKSE:03378's EV-to-FCF is ranked worse than
100% of 346 companies
in the Biotechnology industry
Industry Median: 14.31 vs HKSE:03378: -32.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-30), Hanx Biopharmaceuticals (Wuhan) Co's stock price is HK$27.56. Hanx Biopharmaceuticals (Wuhan) Co does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Hanx Biopharmaceuticals (Wuhan) Co's PE Ratio (TTM) at this moment.

Hanx Biopharmaceuticals (Wuhan) Co  (HKSE:03378) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hanx Biopharmaceuticals (Wuhan) Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.56/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF Related Terms

Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 -13.58

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25
EV-to-FCF 0.00 0.00 -13.58

HKSE:03378 vs VRTX, REGN, RVMD: EV-to-FCF Comparison

For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF falls into.


HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co EV-to-FCF Calculation

Hanx Biopharmaceuticals (Wuhan) Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3727.266/
=

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.56
Price